| PDF - Veröffentlichte Version (296kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-409935
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.40993
Zusammenfassung
Background: Genetic alterations within the epidermal growth factor receptor (EGFR) pathway, including KRAS mutations, have been demonstrated to be associated with response to EGFR inhibitors like cetuximab in colorectal cancers. Mutations in the KRAS gene have been found in 70–90% of pancreatic cancers. Unfortunately, the addition of cetuximab to chemotherapy did not increase response or survival ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik